ResMed: Shareholder Returns Target More Than $1.85 Billion After Free Cash Flow Reaches $1.65 Billion
ResMed said it expects to generate $1.65 billion in free cash flow in fiscal 2026 and return more than $1.85 billion to shareholders via dividends and buybacks in fiscal 2027. In fiscal 2026, revenue rose 10% to $5.65 billion, non-GAAP diluted EPS rose 17% to $11.17, and the quarterly dividend increased 10% to $0.66. Q4 revenue was about $1.46 billion. ResMed also agreed to sell MatrixCare and completed the Noctrix Health acquisition.
How this was made
The 30-second read
Why it matters
The disclosed free cash flow and planned dividends/buybacks provide a concrete framework for valuation and yield expectations, while portfolio actions (MatrixCare sale, Noctrix acquisition) add execution risk and future cash-flow uncertainty.
Market read
A specific, larger capital return target plus a 10% dividend increase can shift investor expectations for shareholder yield and support the stock on valuation and sentiment.
What to watch
The article does not quantify timing details for repurchases, any leverage/capital-structure constraints, or how the MatrixCare sale and Noctrix acquisition affect future cash conversion.
Background
ResMed reported fiscal 2026 cash flow, profitability, and revenue growth, and outlined a larger shareholder return target for fiscal 2027.
Ticker impact
ResMed said it will return more than $1.85B to shareholders in fiscal 2027 after generating $1.65B free cash flow in fiscal 2026.
Likely modest positive price reaction and support on dips, with follow-through depending on how investors value the payout versus growth.
The article provides specific payout magnitude, dividend per-share, and cash flow/EPS figures, which are actionable for yield-focused positioning, though it is not a surprise earnings print or guidance update beyond the stated plan.
Market effects
Reinforces the medical devices/sleep-disorders equipment group’s cash-generation and capital-return profile, potentially supporting peer valuation multiples.
Limited direct regional impact; primarily US-listed large-cap sentiment.
Moderate, as sleep-breathing demand and portfolio reshaping are global but the disclosure is company-specific.
Counterpoint
Investors may discount the payout if they view it as a mature-business reallocation rather than evidence of accelerating growth.
Key entities
- companyResMed
Sleep and breathing health company planning >$1.85B shareholder returns in fiscal 2027 after $1.65B free cash flow in fiscal 2026.
- assetMatrixCare
Software/portfolio component ResMed agreed to sell during the period.
- companyNoctrix Health
Developer of wearable therapeutic devices for restless legs syndrome, acquired by ResMed.
